dutasteride capsule / Generic mfg. - LARVOL DELTA

Effectiveness and Safety of Intralesional Dutasteride in Patients With Androgenic Alopecia: A Systematic Review and Meta-Analysis. (PubMed, J Cosmet Dermatol) - "Intralesional dutasteride appears to be a promising treatment option for AGA, offering localized efficacy with a favorable safety profile. Nonetheless, the current evidence is limited by heterogeneity and a lack of large-scale, high-quality trials. Further standardized research is needed to confirm these findings."

Clinical • Journal • Retrospective data • Review • Alopecia • Immunology

Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics. (PubMed, AAPS J) - "Our results further suggest that the distinct PD profiles of finasteride and dutasteride are attributable to their differing inhibition characteristics against 5αR subtypes (selectivity and affinity). These findings extend our previous work and further support the utility of TMDD-PD modeling for optimizing clinical dose and improving therapeutic outcomes for small-molecule drugs exhibiting TMDD with time-dependent target inhibition."

Journal • PK/PD data

Paradoxical Nonscarring Alopecia Following Mesotherapy with Dutasteride: A Case Series. (PubMed, Int J Trichology) - "The benzyl alcohol and polysiloxane in the cocktail could be the key players having cytotoxic effects, contributing to the development of alopecia. The knowledge of potential adverse effects caused by a drug should always be in the mind of the treating physician."

Journal • Alopecia • Immunology • Pain

Consensus document on the clinical management of frontal fibrosing alopecia: recommendations from Spanish working group on trichology and onychology of the AEDV. (PubMed, Actas Dermosifiliogr) - "Due to its increasing incidence rate in dermatology clinics, and the scarcity of approved specific treatments, the diagnosis and treatment of FFA can be an increasingly common challenge for dermatologists in their routine daily practice.This FFA management consensus was produced via a Delphi methodology involving 22 dermatologists from the Spanish working group on trichology and onychology of the AEDV Because hair loss is irreversible, multimodal therapy with complementary mechanisms and routes should be used starting. with oral dutasteride along with topical and/or intralesional agents; if inflammation persists, hydroxychloroquine should be added to the mix."

Clinical guideline • Journal • Alopecia • Dermatology • Fibrosis • Immunology • Inflammation

Updates in Treatment for Androgenetic Alopecia. (PubMed, Ann Dermatol) - "Topical minoxidil and oral finasteride are the most widely used treatments for AGA, addressing follicular miniaturization...Finasteride and dutasteride, both 5-α-reductase inhibitors that reduce DHT levels in hair follicles, are key androgen-targeting treatments, with newer formulations like topical and injectable options emerging alongside traditional oral forms...This review explores current and emerging treatments for AGA, addressing both androgen-targeted and non-androgen-targeted approaches with an emphasis on their mechanisms, efficacy, and safety. It ultimately aims to provide a comprehensive update on the latest advancements in AGA management."

Journal • Review • Alopecia • CNS Disorders • Immunology

SRY mediates male-specific susceptibility to acute liver injury. (PubMed, Cell Commun Signal) - "Our results suggest that greater SRY expression in males may account for the susceptibility of males ALI. Dutasteride binds specifically to SRY and inhibits its expression, making it a promising therapy for the clinical treatment of ALI."

Journal • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Oncology • Solid Tumor • GSTM2 • PARP1

Monthly versus quarterly dutasteride mesotherapy for male androgenetic alopecia: A randomized trial. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Alopecia • Immunology

No serum estradiol changes with 5-alpha reductase inhibitors for late alopecia in cancer survivors: a retrospective cohort study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • Breast Cancer • Endometrial Cancer • Immunology • Oncology • Solid Tumor

Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study. (PubMed, Medicina (Kaunas)) - "Dutasteride demonstrated superior reductions in prostate volume and PSA, while both agents had comparable effects on sexual and renal function. These findings provide real-world evidence supporting the individualization of 5-ARI therapy according to patient-specific clinical characteristics."

Clinical • HEOR • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia

Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression (clinicaltrials.gov) - P=N/A | N=120 | Active, not recruiting | Sponsor: CHU de Quebec-Universite Laval | Trial completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The carcinogenic mechanism of per- and polyfluoroalkyl substances on clear cell renal cell carcinoma: a combined study of network toxicology and virtual drug screening. (PubMed, Int J Environ Health Res) - "Furthermore, virtual screening identified several promising therapeutic candidates, including Ecteinascidin, Avodart, and Nilotinib, which demonstrated high binding affinity to pivotal molecular targets such as AIM2, HK3, ATP1A1, and ZAP70. This study provides novel insights into the carcinogenic mechanisms of PFAS in ccRCC and proposes new avenues for targeted therapy. However, further experimental and clinical validation is necessary to confirm these findings and translate them into improved patient outcomes, while also addressing broader environmental health concerns related to PFAS exposure."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • ATP1A1 • ZAP70

The Change of Nocturnal Penile Tumescence During Dutasteride Administration. (PubMed, Int J Urol) - No abstract available

Journal • Erectile Dysfunction

Identification of Metabolites for the Novel 5α-Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing. (PubMed, Drug Test Anal) - "Given that other 5α-reductase inhibitors, such as finasteride and dutasteride, are already monitored for their potential impact on doping control, comprehensive metabolic studies of epristeride are crucial for antidoping. Notably, Phase I metabolites (M1 and M2) showed significant binding potential with these targets, whereas the Phase II metabolite (M3) exhibited lower binding stability. These findings provide a detailed understanding of epristeride's metabolic pathways and its potential biological impacts, offering valuable insights for monitoring its presence as a confounding factor in doping control."

Journal • Preclinical • Benign Prostatic Hyperplasia • CYP17A1 • CYP19A1 • CYP3A4 • ER • STAT3

Dutasteride as a Treatment to Support Reduced Drinking: A Randomized Placebo-Controlled Trial. (PubMed, J Addict Med) - "Dutasteride 1 mg daily was efficacious in reducing the number of heavy drinking days and drinks per week in treatment-seeking men, confirming findings from a prior RCT involving 142 men."

Clinical • Journal

Virtual screening of drugs against multiple targets of Alzheimer's disease. (PubMed, J Alzheimers Dis) - "BackgroundDrug repurposing offers a rapid, cost-effective approach for discovering therapies against multiple targets.ObjectiveHere, we screen virtual ligand libraries consisting of 3468 approved drugs against 11 protein targets associated with Alzheimer's disease (AD).MethodsWe employ blind molecular docking, and target amyloid-β (Aβ), microtubule-associated protein tau (MAPT), Apolipoprotein E4 (APOE4), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid-β protein precursor (AβPP), β-secretase (BACE1), brain-derived neurotrophic factor (BDNF), presenilin 1 (PSEN1) and 2 (PSEN2), and α-synuclein (SNCA) proteins using AutoDock Vina.ResultsNotably, multitarget binding recurs among the top-10 ligands with Ergotamine and Dihydroergotamine potentially binding 8; Dutasteride 7; Drospirenone and Nilotinib 6; Adapalene and Conivaptan 5; Bromocriptine 4; and Rolapitant, Irinotecan, Plerixafor, Saquinavir, and Telmisartan 3, out of 11 protein targets. Likewise,..."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension • Inflammation • Pain • APOE • BDNF • MAPT • SNCA

Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study. (PubMed, JAAD Int) - "Twice-weekly and thrice-weekly regimens of dutasteride increased hair growth and were well-tolerated. Although thrice-weekly dutasteride was significantly superior to twice-weekly dutasteride, in terms of hair density and diameter, thrice-weekly dutasteride did not significantly increase hair count over finasteride 1 mg daily."

Journal • Alopecia • Immunology

Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting. (PubMed, Pharmaceuticals (Basel)) - "We designed this study to assess persistence, adherence, and patient satisfaction with FDCs recently introduced to the Polish pharmaceutical market, which contain tamsulosin (an α1-adrenergic receptor antagonist) in combination with solifenacin (a muscarinic receptor antagonist) or dutasteride (a 5-α reductase inhibitor). 2. The use of FDCs increases short-term satisfaction and persistence with therapy, with a mild effect on adherence."

Journal • Benign Prostatic Hyperplasia

Importance of Apelin in Prostate Hyperplasia and Effects of 5 Alpha Reductase on this Mechanism. (PubMed, Arch Esp Urol) - "The significant decrease in apelin levels in the treatment group, along with the apparent relationship between 5dihydrotestosterone (HT) levels and apelin, suggests a potential broader relevance beyond benign cases."

Journal • AR

Dutasteride Infusion in Male Androgenetic Alopecia Using a Novel Drug Delivery Technique: MMP®. (PubMed, Skin Appendage Disord) - "Dutasteride microinfusion using the MMP® technique is effective in treating male AGA. Microneedling with MMP® without any medication is effective in treating male AGA."

Clinical • Journal • Alopecia • Immunology

ARRB2 IN HEPATOCYTES PROMOTE M2 MACROPHAGE POLARIZATION AMELIORATES HEPATIC ISCHEMIA-REPERFUSION INJURY THROUGH UPREGULATING METABOLITE 6-KETOLCA (AASLD 2025) - "Arrb2 in hepatocytes attenuates hepatic IRI by promoting macrophages towards the M2 phenotype through bile acid. Moreover, dutasteride, a selective agonist of Arrb2, emerges as a promising targeted therapeutic agent for the clinical management of liver injury."

Cardiovascular • Hepatology • Liver Failure • Reperfusion Injury

Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We found 24 eligible trials-where the relative efficacy of eight conventional monotherapies and seven alternative (nonconventional, over-the-counter) products was determined. The current NMA study confirms the efficacy of conventional monotherapies such as oral dutasteride, topical/oral minoxidil, and oral/topical finasteride for male AGA. We have provided guidance regarding the relative efficacy of some alternative (nonconventional, over-the-counter) agents (e.g., melatonin (topical) and rosemary oil (topical)) compared to conventional treatments."

Clinical • Journal • Retrospective data • Review • Alopecia • Immunology

A Canadian Consensus on Androgenetic Alopecia: Approach and Management. (PubMed, J Cutan Med Surg) - "Seven interventions are recommended, including oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; platelet-rich plasma; microneedling; and oral minoxidil. Five interventions are recommended with near consensus: intralesional dutasteride; ketoconazole shampoo; low level laser therapy; aminexil; as part of a regimen and 17 are not recommended (adenosine; cetirizine; carboxytherapy; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; basic Fibroblast Growth Factor (bFGF); flutamide)."

Journal • Alopecia • Immunology • FGF

Hair regrowth in male androgenetic alopecia combining microneedling-assisted delivery of a minoxidil-based formulation and oral dutasteride: a case report (EADV 2025) - "This case highlights the synergistic effect of combining microneedling mesotherapy with topical and systemic therapies for AGA. The integration of procedural and pharmacological treatments may accelerate clinical response and enhance patient satisfaction without increasing adverse effects. Multimodal strategies should be considered in moderate-to-severe AGA, especially in cases with high aesthetic concern."

Case report • Clinical • Alopecia • Immunology

Trichology in the Age of Misinformation: Bridging the Gap Between Evidence-Based Dermatology and Social Media Narratives (EADV 2025) - "Despite the availability of evidence-based treatments such as Minoxidil, Finasteride, Dutasteride, and Platelet-Rich Plasma (PRP), patients are frequently exposed to misinformation that promotes unverified, often ineffective remedies. Misinformation in trichology poses a growing challenge to evidence-based dermatology. However, it also offers an opportunity for dermatologists to reclaim the narrative through responsible use of social media and enhanced patient communication. By actively addressing myths, setting realistic expectations, and simplifying scientific information for digital platforms, dermatologists can build credibility, improve adherence, and protect patients from the pitfalls of pseudoscience."

Alopecia • Dermatology

Mesotherapy and Iontophoresis with Dutasteride: What Do We Know So Far? (EADV 2025) - "In conclusion, both mesotherapy and Tricopat offer promising, minimally invasive approaches for delivering dutasteride in AGA treatment."

Aesthetic Medicine • Alopecia • CNS Disorders • Immunology